| Iupac name | 4-Propan-2-yl-2-[3-(trifluoromethyl)phenyl]morpholine |
|---|---|
| Width | 250px |
| Tradename | Conflictan |
| Legal status | Rx-only |
| Routes of administration | Oral |
| Cas number | 26629-87-8 |
| Index2 label | HCl |
| Cas number 2 | 26629-86-7 |
| Unii 2 | E10FW59D1I |
| Atc prefix | N06 |
| Atc suffix | AX10 |
| Pubchem | 432824 |
| Chemspiderid | 382782 |
| Unii | V4WLW77V5Q |
| Kegg | D07340 |
| Synonyms | CERM-1766 |
| C | 14 |
| H | 18 |
| F | 3 |
| N | 1 |
| O | 1 |
| Smiles | O1CCN(C(C)C)CC1c2cc(C(F)(F)F)ccc2 |
Oxaflozane (INN; brand name Conflictan) is an antidepressant and anxiolytic drug that was introduced by Solvay in France in 1982 for the treatment of depression but has since been discontinued.[1][2][3][4] It is a prodrug of flumexadol (N-dealkyloxaflozane; 2-(3-trifluoromethylphenyl)morpholine; CERM-1841 or 1841-CERM), which is reported to act as an agonist of the serotonin 5-HT1A (pKi = 7.1) and 5-HT2C (pKi = 7.5) receptors and, to a much lesser extent, of the 5-HT2A (pKi = 6.0) receptor.[4][5] In addition to its serotonergic properties, oxaflozane may also produce anticholinergic side effects at high doses, namely in overdose.[6]
See also
References
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 909–. ISBN 978-1-4757-2085-3.
- ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 766. ISBN 3-88763-075-0.
- ^ Sittig M (1988). Pharmaceutical Manufacturing Encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. p. 1122. ISBN 0-8155-1144-2.
- ^ Bégué JP, Bonnet-Delpon D (2 June 2008). "Drugs for CNS Disorders". Bioorganic and Medicinal Chemistry of Fluorine. John Wiley & Sons. pp. 303–. ISBN 978-0-470-28187-1.
- ^ Leysen DC (February 1999). "Selective 5-HT2C agonists as potential antidepressants". IDrugs. 2 (2): 109–20. PMID 16160946
- ^ Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E (1992). "Oxaflozane overdose in a child". Journal of Toxicology. Clinical Toxicology. 30 (1): 123–6. doi:10.3109/15563659208994452. PMID 1542141
Further reading
- Rascol A, Maurel H, David J, Layani M (1974). "[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]" (in French). Thérapie. 29 (1): 95–9. PMID 4603757
- Hache J, Duchene-Marullaz P, Streichenberger G (1974). "[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]" (in French). Thérapie. 29 (1): 81–93. PMID 4849381
- Constantin M, Pognat JF (1979). "Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites". Arzneimittel-Forschung. 29 (1): 109–14. PMID 582104
- Bertolino A, palermo M, Porro V (1985). "Un nouvel antidépresseur non tricyclique, l'oxaflozane, dans le traitement des syndromes anxio-dépressifs" [Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes]. Acta Therapeutica. 11 (2): 209–218.
- Aguglia E (1986). "On the therapetic value of oxaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations". Acta Therapeutica. 12 (3): 259–268.